文献速递血栓与止血

直接口服抗凝药预防门诊癌症患者血栓形成的系统评价与荟萃分析

Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: A systematic review and meta-analysis.
PubMed 文献 · J Thromb Haemost · 2019-09-17

该系统评价与荟萃分析纳入2项随机对照试验共1415例接受全身化疗的门诊癌症患者,比较直接口服抗凝药(DOAC)与安慰剂。

要点

  • 低剂量DOAC降低高危门诊癌症患者6个月内总体VTE风险(RR 0.56)。
  • 症状性VTE风险可能降低(RR 0.58),但置信区间宽且不显著。
  • 大出血风险有升高趋势(RR 1.96),需权衡出血风险。

核心结论

  • 低剂量DOAC降低开始全身化疗的高危癌症患者总体VTE发生率,可能降低症状性VTE但增加出血可能性。

研究设计与样本

  • 系统评价与荟萃分析,检索EMBASE、MEDLINE和CENTRAL数据库,纳入成人门诊癌症患者预防性使用DOAC的III期随机对照试验,最终2项研究共1415例受试者纳入荟萃分析。

主要发现

  • Khorana评分高危(3+)患者获得的VTE绝对风险降低最大。

关键数值与推荐

  • 纳入标准:成人门诊癌症患者、预防性使用DOAC、随机对照试验;排除儿童、住院或术后、治疗性DOAC指征及非III期随机对照试验。

临床怎么用

  • 对于开始全身化疗的高危门诊癌症患者,可考虑低剂量DOAC预防VTE,但需个体化评估出血风险。

局限性

  • 仅纳入2项研究共1415例受试者,样本量有限;症状性VTE和大出血的置信区间较宽,结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It is unclear if direct oral anticoagulant (DOAC) is efficacious and safe for prophylaxis of venous thromboembolism (VTE) in ambulatory patients with cancer. METHODS: We performed a systematic review using EMBASE, MEDLINE, and CENTRAL. Inclusion criteria included adult ambulatory patients with cancer, prophylactic use of DOAC, and randomized controlled trials. Exclusion criteria included pediatric patients, inpatient or postoperative setting, therapeutic indication of DOAC, or non-phase III randomized controlled trial. Two authors screened/reviewed articles and abstracted the data. Meta-analysis was performed using random-effects model. Efficacy outcome included overall and symptomatic VTE incidence during the first 6 months. Safety outcomes included major bleeding and clinically relevant non-major bleeding (CRNMB) incidence during the on-treatment period. Subgroup analysis was performed for intermediate- and high-risk Khorana score. RESULTS: A total of 202 records were identified and 28 full-text articles were assessed. Two studies with 1415 participants were included for meta-analysis. For DOAC vs placebo, the relative risks for overall and symptomatic VTE incidence by 6 months were 0.56 (0.35-0.89) and 0.58 (0.29-1.13), respectively. The relative risks for major bleeding and CRNMB while on-treatment were 1.96 (0.80-4.82) and 1.28 (0.74-2.20), respectively. Patients with high-risk Khorana score (3+) derived the largest absolute risk reduction of VTE. CONCLUSIONS: Low-dose DOAC reduces the rate of overall VTE in higher risk cancer patients starting systemic chemotherapy. It may reduce the rate of symptomatic VTE but increase the likelihood of bleeding.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Li A, Kuderer NM, Garcia DA, et al. Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: A systematic review and meta-analysis. J Thromb Haemost. 2019. PMID: 31420937. doi:10.1111/jth.14613

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。